Global X China Biotech Innovation ETF
CHB
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- United States of America
- IPO Date
- Sep 25, 2020
- CIK
- 0001432353
- Similar Companies
- Business
- Global X China Biotech Innovation ETF (CHB) is an exchange-traded fund that seeks to provide investment results corresponding generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index. The fund invests in a market-cap weighted portfolio of Chinese companies directly involved in the biotechnology industry, including biotechnology (78.1% weighting), pharmaceuticals generic (10.2%), pharmaceuticals other (9.0%), medical specialties (1.7%), and pharmaceuticals major (1.1%); top holdings comprise CSPC Pharmaceutical Group Ltd. (8.70%), Chongqing Zhifei Biological Products Co. Ltd. (7.99%), Changchun High & New Technology Industry Group Inc. (7.90%), Walvax Biotechnology Co. Ltd. (6.01%), and Wuxi Biologics Cayman Inc. (5.67%). It targets growth-oriented biotech firms benefiting from China's expanding healthcare sector, with securities listed on exchanges such as the Hong Kong Stock Exchange, Shanghai-Hong Kong Stock Connect, Shenzhen-Hong Kong Stock Connect, New York Stock Exchange, and NASDAQ; the fund holds 44 positions, exhibits a net expense ratio of 0.65%, and maintains net assets of approximately $1.44 million as of recent data. Launched on September 22, 2020, and listed on Nasdaq (ticker: CHB; CUSIP: 37954Y251), the ETF is managed by Global X Management Company LLC, a subsidiary of Mirae Asset Global Investments, with headquarters in New York and primary operations focused on the U.S. market while providing exposure to Chinese biotech companies operating predominantly in mainland China, Hong Kong, and international listings. In a significant operational change, the fund underwent liquidation announced on January 19, 2024, with cash settlement to shareholders completed by February 2024 at approximately $6.72 per share, resulting in the termination of trading and acceleration of option expirations; no subsequent relaunches, acquisitions, partnerships, funding rounds, or new product offerings have been reported for CHB in the last 1-2 years, reflecting its non-diversified status and heightened volatility tied to China's biotech sector amid regulatory, economic, and market risks.